PUMA BIOTECHNOLOGY, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PBYI$8.40+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| ITEM 9B. | OTHER INFORMATION |
|---|
During thethree months* ended December 31,2025, no director or officer (as defined in Rule*16a*-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule*10b5*-1 trading arrangement” or “non-Rule*10b5*-*1 trading arrangement,” as each term is defined in Item408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.